ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Lung Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Milano, Lombardia, ITA:

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3

FibroGen
FibroGen

Milano, Italy and 89 other locations

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer...

Active, not recruiting
Chemotherapy-induced Thrombocytopenia
Other: Placebo
Biological: Romiplostim

Phase 3

Amgen
Amgen

Milano, Italy and 116 other locations

or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...

Enrolling
Pancreatic Cancer Metastatic
Pancreatic Cancer Stage IV
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 2, Phase 3

Panbela Therapeutics

Milano, Lombardia, Italy and 91 other locations

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Milan, Italy and 137 other locations

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumor...

Enrolling
Exocrine Pancreatic Cancer
Carcinoma, Non-Small-Cell Lung
Drug: cisplatin
Drug: carboplatin

Phase 2

Seagen
Seagen

Milano, Other, Italy and 63 other locations

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age...

Enrolling
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: Paclitaxel

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Milano, Italy and 73 other locations

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immun...

Enrolling
Pancreatic Cancer Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion
Drug: zenocutuzumab (MCLA-128)

Phase 2

Merus

Milan, Italy and 64 other locations

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given...

Active, not recruiting
BRAF Mutant Colorectal Cancer
Lung Squamous Cell Cancer
Biological: PDR001
Drug: LGK974

Phase 1

Novartis
Novartis

Milano, MI, Italy and 19 other locations

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor...

Enrolling
Colorectal Cancer (CRC)
Non-Small Cell Lung Cancer (NSCLC)
Drug: RMC-6291

Phase 1

Revolution Medicines
Revolution Medicines

Milano, Italy and 63 other locations

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor...

Active, not recruiting
Breast Cancer
Papillary Thyroid Cancer
Drug: Entrectinib

Phase 2

Roche
Roche

Milano, Lombardia, Italy and 122 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems